ATE255411T1 - Hyaluronsäurerezeptoren bindende stoffe und deren verwendung zur behandlung von tumoren und restenose - Google Patents

Hyaluronsäurerezeptoren bindende stoffe und deren verwendung zur behandlung von tumoren und restenose

Info

Publication number: ATE255411T1
Authority: AT; Austria
Prior art keywords: cac; arg; identified; amino acids; treatment
Prior art date: 1995-12-27

Application number

AT96941564T

Other languages

English (en)

Inventor

Eva Turley

Original Assignee

Jagotec Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-27

Filing date

1996-12-23

Publication date

2003-12-15

1996-12-23 Application filed by Jagotec Ag filed Critical Jagotec Ag

2003-12-15 Application granted granted Critical

2003-12-15 Publication of ATE255411T1 publication Critical patent/ATE255411T1/de

Links

101001054921 Homo sapiens Lymphatic vessel endothelial hyaluronic acid receptor 1 Proteins 0.000 title 1
102100026849 Lymphatic vessel endothelial hyaluronic acid receptor 1 Human genes 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
208000037803 restenosis Diseases 0.000 title 1
239000000126 substance Substances 0.000 title 1
150000001413 amino acids Chemical class 0.000 abstract 4
239000003814 drug Substances 0.000 abstract 4
239000011230 binding agent Substances 0.000 abstract 3
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
229920002674 hyaluronan Polymers 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
229940124597 therapeutic agent Drugs 0.000 abstract 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 abstract 1
229940099552 hyaluronan Drugs 0.000 abstract 1
229960003160 hyaluronic acid Drugs 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70585—CD44
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Cell Biology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Inorganic Chemistry (AREA)
Vascular Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Peptides Or Proteins (AREA)
Steroid Compounds (AREA)

AT96941564T 1995-12-27 1996-12-23 Hyaluronsäurerezeptoren bindende stoffe und deren verwendung zur behandlung von tumoren und restenose ATE255411T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CA002166155A CA2166155C (en)	1995-12-27	1995-12-27	Agents binding to hyaluronic acid binding domains and the use thereof
PCT/CA1996/000870 WO1997024111A2 (en)	1995-12-27	1996-12-23	Novel hyaluronic acid receptors binding agents and the use thereof

Publications (1)

Publication Number	Publication Date
ATE255411T1 true ATE255411T1 (de)	2003-12-15

Family

ID=4157242

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96941564T ATE255411T1 (de)	1995-12-27	1996-12-23	Hyaluronsäurerezeptoren bindende stoffe und deren verwendung zur behandlung von tumoren und restenose

Country Status (15)

Country	Link
EP (1)	EP0874624B1 (de)
JP (1)	JP4210330B2 (de)
KR (1)	KR100476782B1 (de)
AT (1)	ATE255411T1 (de)
AU (1)	AU725478B2 (de)
BR (1)	BR9612355A (de)
CA (1)	CA2166155C (de)
DE (1)	DE69630974T2 (de)
ES (1)	ES2211996T3 (de)
HU (1)	HU226598B1 (de)
IL (1)	IL124828A0 (de)
NO (1)	NO982935L (de)
PL (1)	PL327542A1 (de)
WO (1)	WO1997024111A2 (de)
ZA (1)	ZA9610840B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2237051A1 (en) *	1997-12-19	1999-06-19	Eva A. Turley	Enhanced affinity hyaluronan binding peptides
SE0101854L (sv) *	2001-05-28	2002-11-29	Bioneris Ab	Användning av en förening med en negativt laddad region av grupper för behandling av restenos.
WO2004060404A1 (ja) *	2002-12-27	2004-07-22	Chugai Seiyaku Kabushiki Kaisha	薬物担体
EP1896386B1 (de) *	2005-06-08	2012-09-05	Cangene Corporation	Hyaluronsäurebindende peptide fördern die immunabwehr gegen pathogene bakterien
RU2012157597A (ru)	2010-05-31	2014-07-20	Лондон Хелс Сайенсис Сентр Рисерч Инк.	Rhamm-связывающие пептиды
KR101383941B1 (ko)	2012-03-09	2014-04-10	동아에스티 주식회사	피록시캄 또는 약제학적으로 허용되는 그의 염과 히알루론산 또는 약제학적으로 허용되는 그의 염의 안정한 액상 조성물 및 그 제조방법
US10766927B2 (en)	2012-11-25	2020-09-08	The Regents Of The University Of California	Peptides that stimulate subcutaneous adipogenesis
WO2015184125A1 (en)	2014-05-28	2015-12-03	The Regents Of The University Of California	Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
US10562935B2 (en)	2015-03-20	2020-02-18	London Health Sciences Centre Research Inc.	Stapled peptides and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1340994C (en) *	1989-09-21	2000-05-16	Rudolf Edgar Dr. Falk	Treatment of conditions and disease
CA2122551A1 (en) *	1994-04-29	1995-10-30	Rudolf Edgar Falk	Clearing of atherosclerosis
GB9207949D0 (en) *	1992-04-09	1992-05-27	Univ Manitoba	Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility
AU3159595A (en) *	1994-08-30	1996-03-22	Hyal Pharmaceutical Corporation	Hyaluronic acid and derivatives for modulation of cellular activity

1995
- 1995-12-27 CA CA002166155A patent/CA2166155C/en not_active Expired - Lifetime
1996
- 1996-12-23 DE DE69630974T patent/DE69630974T2/de not_active Expired - Lifetime
- 1996-12-23 EP EP96941564A patent/EP0874624B1/de not_active Expired - Lifetime
- 1996-12-23 KR KR10-1998-0704359A patent/KR100476782B1/ko not_active Expired - Fee Related
- 1996-12-23 AT AT96941564T patent/ATE255411T1/de not_active IP Right Cessation
- 1996-12-23 ZA ZA9610840A patent/ZA9610840B/xx unknown
- 1996-12-23 AU AU10912/97A patent/AU725478B2/en not_active Ceased
- 1996-12-23 IL IL12482896A patent/IL124828A0/xx not_active IP Right Cessation
- 1996-12-23 JP JP52393097A patent/JP4210330B2/ja not_active Expired - Fee Related
- 1996-12-23 WO PCT/CA1996/000870 patent/WO1997024111A2/en not_active Ceased
- 1996-12-23 ES ES96941564T patent/ES2211996T3/es not_active Expired - Lifetime
- 1996-12-23 BR BR9612355-9A patent/BR9612355A/pt not_active Application Discontinuation
- 1996-12-23 PL PL96327542A patent/PL327542A1/xx unknown
- 1996-12-23 HU HU9902059A patent/HU226598B1/hu not_active IP Right Cessation
1998
- 1998-06-24 NO NO982935A patent/NO982935L/no unknown

Also Published As

Publication number	Publication date
WO1997024111A3 (en)	1997-10-02
NO982935L (no)	1998-08-27
AU1091297A (en)	1997-07-28
PL327542A1 (en)	1998-12-21
CA2166155A1 (en)	1997-06-28
DE69630974T2 (de)	2004-10-28
HUP9902059A3 (en)	2000-07-28
CA2166155C (en)	2008-02-05
EP0874624A2 (de)	1998-11-04
JP2000506502A (ja)	2000-05-30
DE69630974D1 (de)	2004-01-15
AU725478B2 (en)	2000-10-12
ES2211996T3 (es)	2004-07-16
ZA9610840B (en)	1997-06-27
BR9612355A (pt)	1999-12-28
JP4210330B2 (ja)	2009-01-14
NO982935D0 (no)	1998-06-24
WO1997024111A2 (en)	1997-07-10
HUP9902059A2 (hu)	2000-04-28
KR100476782B1 (ko)	2005-07-18
KR19990072058A (ko)	1999-09-27
IL124828A0 (en)	1999-01-26
EP0874624B1 (de)	2003-12-03
HU226598B1 (hu)	2009-04-28

Similar Documents

Publication	Publication Date	Title
NZ504026A (en)	2002-12-20	Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
EA199800393A1 (ru)	1998-12-24	Композиции и способы их применение для лечения поражения костей
BR0011000A (pt)	2002-02-19	Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico
ATE399553T1 (de)	2008-07-15	Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE185268T1 (de)	1999-10-15	Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ATE467425T1 (de)	2010-05-15	Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
BR9813373A (pt)	2000-10-03	Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
ATE328605T1 (de)	2006-06-15	Verwendung von insulin zur behandlung von knorpelkrankheiten
AU3368497A (en)	1998-01-07	Human dnase i hyperactive variants
ATE295734T1 (de)	2005-06-15	Verwendung von fibroblasten-wachstumsfaktor analogen zur stimulation des knochenwachstums
PT942740E (pt)	2004-01-30	Terapia de combinacao utilizando uma proteina de ligacao de tnf para tratamento de doencas mediadas por tnf
JO2373B1 (en)	2006-12-12	W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
HUT77380A (hu)	1998-04-28	Kombinált gyógyszerkészítmény alkalmazása sclerosis multiplex (MS) és más demielizáló állapotok kezelésére
WO2001043732A3 (en)	2002-03-21	Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
BR9813318A (pt)	2000-08-22	Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
ATE255411T1 (de)	2003-12-15	Hyaluronsäurerezeptoren bindende stoffe und deren verwendung zur behandlung von tumoren und restenose
TW200640944A (en)	2006-12-01	VGF polypeptides and methods of treating VGF-related disorders
DE69725879D1 (de)	2003-12-04	VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
ATE214272T1 (de)	2002-03-15	Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE313561T1 (de)	2006-01-15	Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
MXPA00010254A (es)	2002-08-06	Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
YU60199A (sh)	2002-09-19	Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
ATE293994T1 (de)	2005-05-15	Multivalente rekombinante antikörper zur behandlung von hrv infektionen
ATE295731T1 (de)	2005-06-15	Olanzapine zur behandlung von drogenmissbrauch
UA66749C2 (en)	2004-06-15	Actin-resistant variants of human dnase i, isolated nucleic acid, a method for treatment of patients suffering from pulmonary diseases

Legal Events

Date	Code	Title	Description
2004-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties